Published in Gene Therapy Weekly, January 31st, 2002
"Hematopoietic stem cells (HSCs) represent an important target for the treatment of various blood disorders," explained Yan Cui and colleagues at Johns Hopkins University's Johns Hopkins Oncology Center in Baltimore, Maryland. "As the source of critical cells within the immune system, genetic modification of HSCs can also be used to modulate immune responses."
Self-inactivating (SIN) lentiviral vectors can be used to transfect stem cells, and can target transgene expression to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly